Peer Review History

Original SubmissionJanuary 11, 2024
Decision Letter - Elvan Wiyarta, Editor
Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

PONE-D-23-42287Correlation between Novel Inflammatory Markers and Carotid Atherosclerosis: a Cross-Sectional StudyPLOS ONE

Dear Dr. qi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Elvan Wiyarta, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"The study was supported by the National Natural Science Foundation of China (Grant No.81571373, No.81601217, No.82001491), Natural Science Foundation of Hubei Province of China (Grant No. 2017CFB627), Health Commission of Hubei Province scientific research project (Grant No. WJ2021M247) and Scientific Research Fund of Wuhan Union Hospital (Grant No.2019)."

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. In this instance it seems there may be acceptable restrictions in place that prevent the public sharing of your minimal data. However, in line with our goal of ensuring long-term data availability to all interested researchers, PLOS’ Data Policy states that authors cannot be the sole named individuals responsible for ensuring data access (http://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-sharing-methods).

Data requests to a non-author institutional point of contact, such as a data access or ethics committee, helps guarantee long term stability and availability of data. Providing interested researchers with a durable point of contact ensures data will be accessible even if an author changes email addresses, institutions, or becomes unavailable to answer requests.

Before we proceed with your manuscript, please also provide non-author contact information (phone/email/hyperlink) for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If no institutional body is available to respond to requests for your minimal data, please consider if there any institutional representatives who did not collaborate in the study, and are not listed as authors on the manuscript, who would be able to hold the data and respond to external requests for data access? If so, please provide their contact information (i.e., email address). Please also provide details on how you will ensure persistent or long-term data storage and availability.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Please address all review from the reviewers below

Please also make the rebuttal letter to address each of the issue

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Authors, I want to say that this study fulfills the novelty and offers an important result. But, I am concerned about several issues in your manuscript. I think you need to explain more the main rationale of the study and explain why the variable is choosen to investigate. The other comments on the issues have been embedded in the reviewed manuscript. I hope you can revise for the improvement of your manuscript.

line 3 ....In the title the authors mention a cross sectional study design, but in the method section the authors mention the different study design

line 77 ...In the introduction section... Can the authors mention possible factors leading to chronic inflammation which especially is significant in cerebrovascular atherosclerosis?

Line 99... Can authors elaborate why and how significant this variable (CAS) is considered to be investigated in the study. I suggest the explanation can be the rationale of the selection of the CAS in this study?

Line 101..The authors should state consistently the study design

Line 109 ...Can the authors specify the inclusion criteria of subject selection in this study, it can be range of age, gender, and some specific health-related status, etc.

Line 116 ..Do the authors consider the history of TIA, diabetes, smoking history, neck blunt trauma, etc as the confounding factors or exclusion criteria?

Line 120...Please the author provide the timing of lab data collection

Line 141...Is there any temporal relationship between this medical history and the timing of lab data collection?

Line 164..These criteria of subject selection are not yet mentioned in the method section

Line 167 - 172 ...There are several variables which are different between the CAS group and non CAS group. Can the authors interpret these findings?

Line 204 ..Can the authors show the statistical analysis for adjusting these confounding factors?

Reviewer #2: I evaluated this study in which new inflammatory markers were used to predict coronary artery disease. The fact that the number of patients in the study is quite remarkable increases the power of the study. New inflammatory markers were found to be significantly correlated with carotid atherosclerosis; However, NLPR was found to be the most appropriate inflammatory marker to predict the risk of carotid atherosclerosis. These markers may be practical, accessible and inexpensive for the clinician to use in their daily routine. In general, the English language of the well-designed and written study should be reviewed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Minor Revision.docx
Revision 1

Journal Requirements:

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Yes, I've checked that my manuscript meets PLOS ONE's style.

2.Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. I have affirmed the relevant content in my cover letter.

3.In this instance it seems there may be acceptable restrictions in place that prevent the public sharing of your minimal data. However, in line with our goal of ensuring long-term data availability to all interested researchers, PLOS’ Data Policy states that authors cannot be the sole named individuals responsible for ensuring data access (http://journals.plos.org/plosone/s/data-availability#loc-acceptable-data-sharing-methods).

Response: I'll attach my raw data to the support information.

4.Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: All values in the tables and images in the article are based on raw data and statistically analysed. I'll attach my raw data to the support information.

5.Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: No changes to original references, but we have added some references.

Review Comments to the Author:

line 3 ....In the title the authors mention a cross sectional study design, but in the method section the authors mention the different study design

Response: This study can be described as both cross sectional study and retrospective case-control study, but it prefers retrospective case-control study, so we describe it uniformly as retrospective case-control study both in the title and in the method section.

line 77 ...In the introduction section... Can the authors mention possible factors leading to chronic inflammation which especially is significant in cerebrovascular atherosclerosis?

Response: Possible factors leading to chronic inflammation have been added in the preamble section.

Line 99... Can authors elaborate why and how significant this variable (CAS) is considered to be investigated in the study. I suggest the explanation can be the rationale of the selection of the CAS in this study?

Response: In line 73-76 we add an explanation of why CAS was chosen for the study.

Line 101...The authors should state consistently the study design

Response: We modify study design consistently to retrospective case-control study both in the title and in the method section.

Line 109 ...Can the authors specify the inclusion criteria of subject selection in this study, it can be range of age, gender, and some specific health-related status, etc.

Response: The population included in this study was greater than 18 years age and underwent carotid vascular ultrasound. We have added to the methods section the inclusion criteria in line 117-118.

Line 116 ...Do the authors consider the history of TIA, diabetes, smoking history, neck blunt trauma, etc as the confounding factors or exclusion criteria?

Response: We consider the history of diabetes, hypertension, smoking history, etc as the confounding factors, but the history of TIA and neck blunt trauma were not documented in our medical history and the history of TIA and neck blunt trauma are not a cause of atherosclerosis.

Line 120...Please the author provide the timing of lab data collection

Response: Clinical data and lab data were collected together, and the time of data collection is described on line 115.

Line 141...Is there any temporal relationship between this medical history and the timing of lab data collection?

Response: This study was retrospective. The medical history was recorded on the same day as the laboratory data, and we collected the history and laboratory data uniformly several years after these data existed.

Line 154...Can the authors show the statistical analysis for these confounding factors?

Response: We describe the statistical results of the confounding factors in Table 1 and calculate the differences between the two groups. However, because subsequent studies have focused on novel inflammatory indicators and adding confounding factors may affect the aesthetics of forest plots of novel inflammatory indicator ORs , the analysis of confounding factors was not continued in subsequent logistic regressions.

Line 164...These criteria of subject selection are not yet mentioned in the method section

Response: We have added to the methods section the inclusion criteria in line 117-118.

Line 167 - 172 ...There are several variables which are different between the CAS group and non CAS group. Can the authors interpret these findings?

Response: We have added a relevant explanation of this result in the discussion section in line 130-150.

Line 204...Can the authors show the statistical analysis for adjusting these confounding factors?

Response: We describe the statistical results of the confounding factors in Table 1 and calculate the differences between the two groups. However, because subsequent studies have focused on novel inflammatory indicators and adding confounding factors may affect the aesthetics of forest plots of novel inflammatory indicator ORs , the analysis of confounding factors was not continued in subsequent logistic regressions.

Line 333...The authors can explain in the discussion section about the possible interaction between the inflammatory markers and the known risk factors/comorbid according to the baseline characteristics of the subjects

Response: We have added a relevant explanation of the baseline characteristics and explained the interactions that exist between inflammatory markers and known co-morbidities in the discussion section in line 130-150.

Line 336...The authors need to mention the strength and limitation of the study

Response: In the last paragraph of the discussion section, we describe the strengths and limitations of this study.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Elvan Wiyarta, Editor

Correlation between Novel Inflammatory Markers and Carotid Atherosclerosis: a Retrospective Case-control Study

PONE-D-23-42287R1

Dear Dr. qi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Elvan Wiyarta, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Ihave reviewed the article. It s a good study. I hope that the results will be beneficial.

thank you

sincerely yours

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .